Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized 4-arm pilot dose-finding study of P.L.E.A.S.E. assisted versus standard topical imiquimod for actinic keratosis
2010-022502-40Phase 2Completed
- Sponsor
- Pantec Biosolutions AG
- Start
- Sep 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of imiquimod in actinic keratosis (AK) (4 arms), sponsored by Pantec Biosolutions AG. Primary endpoints: Strength of imiquimod therapeutic effect at week 3 and Time to imiquimod therapeutic effect. Started Sep 2010; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2010-022502-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022502-40.